|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bariatric surgery in patients with non-alcoholic fatty liver disease-from pathophysiology to clinical effects显示文摘Non-alcoholic fatty liver disease(NAFLD) is increasingly recognized as a significant liver disease,and it covers the disease spectrum from simple steatosis with a risk of development of non-alcoholic steatohepatitis(NASH) to fibrosis,subsequent cirrhosis,end-stage liver failure,and liver cancer with a potential need for liver transplantation.NAFLD and NASH are closely related to obesity,metabolic syndrome,and type 2 diabetes(T2 D).The role of gut hormones,especially glucagon-like peptide 1(GLP-1),is important in NAFLD.Bariatric surgery has the potential for inducing great weight loss and may improve the symptoms of metabolic syndrome and T2 D.Recent data demonstrated significant effects of bariatric surgery on GLP-1 and other gut hormones and important lipid metabolic and inflammatory abnormalities in the pathophysiology of NAFLD.Therefore,bariatric surgery may reverse the pathological liver changes in NAFLD and NASH patients.In the present review,we describe NAFLD and NASH pathophysiology and the primary effects of bariatric surgery on metabolic pathways.We performed a systematic review of the beneficial and harmful effects and focused on changes in liver disease severity in NAFLD and NASH patients.The specific focus was liver histopathology as assessed by the invasive liver biopsy.Additionally,we reviewed several non-invasive methods used for the assessment of liver disease severity following bariatric surgery. | Tea L Laursen Christoffer A Hagemann Chunshan Wei Konstantin Kazankov Karen L Thomsen Filip K Knop Henning Grønbæk | 2019 | World Journal of Hepatology2019，11，2： | 11 |
| 2 | 非酒精性脂肪性肝病中脂肪组织胰岛素抵抗与肝巨噬细胞的相互作用显示文摘【据《J Hepatol》2019年11月报道】题:非酒精性脂肪性肝病中脂肪组织胰岛素抵抗与肝巨噬细胞的相互作用(作者Rosso C等)非酒精性脂肪性肝病(NAFLD)和脂肪性肝炎(NASH)的发病机制可能是由于紊乱的代谢环境与肝脏炎症和纤维化的局部介质之间的相互作用。该研究旨在阐明巨噬细胞活化、靶器官/组织胰岛素抵抗(IR)与肝损伤之间的相互作用。 | 赵优优 高普均 ROSSO C KAZANKOV K YOUNES R | 2020 | 临床肝胆病杂志2020，36，3： | 2 |
| 3 | Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C 显示文摘 | Kazankov K Ban:era F Mi~ ller tt J | 2014 | Hepatology2014，60，2： | 1 |
| 4 | P1007 SOLUBLE CD163, A MACROPHAGE ACTIVATION MARKER, IS INDEPENDENTLY ASSOCIATED WITH FIBROSIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS B AND C显示文摘 | K. Kazankov F. Barrera H.J. M?ller B.M. Bibby H. Vilstrup J. George H. Gr?nb?k | 2014 | Journal of Hepatology2014，，1： | 1 |
| 5 | Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis显示文摘 | Heeboll S Kazankov K Poulsen MK | 2012 | Ugeskr Laeger2012，174，8： | 1 |
| 6 | Restingmyocardial dysfunction in cirrhosis quantified by tissue Dopplerimaging显示文摘 | Kazankov K Holland Fischer P Andersen NH | 2011 | Liver Int2011，31，4： | 1 |
| 7 | Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging显示文摘 | Kazankov K Holland Fischer P Andersen NH | 2011 | Liver Int2011，31，： | 1 |
| 8 | Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging 显示文摘 | Kazankov Holland-Fischer P Andersen NH | 2011 | Liver International2011，31，4： | 1 |
| 9 | Resting myo- cardial dysfunction in cirrhosis quantified by tissue Doppler imaging 显示文摘 | Kazankov K Holland - Fischer P Andersen NH | 2011 | Liver Int2011，31，4： | 1 |
| 10 | Liver-related effects of chronic hepatitis C antiviral treatment显示文摘More than five years ago,the treatment of hepatitis C virus infection was revolutionized with the introduction of all-oral direct-acting antiviral(DAA)drugs.They proved highly efficient in curing patients with chronic hepatitis C(CHC),including patients with cirrhosis.The new DAA treatments were alleged to induce significant improvements in clinical outcome and prognosis,but the exact cause of the expected benefit was unclear.Further,little was known about how the underlying liver disease would be affected during and after viral clearance.In this review,we describe and discuss the liver-related effects of the new treatments in regards to both pathophysiological aspects,such as macrophage activation,and the time-dependent effects of therapy,with specific emphasis on inflammation,structural liver changes,and liver function,as these factors are all related to morbidity and mortality in CHC patients.It seems clear that antiviral therapy,especially the achievement of a sustained virologic response has several beneficial effects on liver-related parameters in CHC patients with advanced liver fibrosis or cirrhosis.There seems to be a timedependent effect of DAA therapy with viral clearance and the resolution of liver inflammation followed by more discrete changes in structural liver lesions.These improvements lead to favorable effects on liver function,followed by an improvement in cognitive dysfunction and portal hypertension.Overall,the data provide knowledge on the several beneficial effects of DAA therapy on liverrelated parameters in CHC patients suggesting short-and long-term improvements in the underlying disease with the promise of an improved longterm prognosis. | Tea L Laursen Thomas D Sandahl Konstantin Kazankov Jacob George Henning Gronbæk | 2020 | World Journal of Gastroenterology2020，26，22： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员